APOE ε4 or ApoE4?
A Clinician’s Guide to Correct Nomenclature
The distinction between the gene, the allele, and the protein isoform is not semantic — it reflects a precise molecular reality. Using the correct term in the correct context matters for scientific communication, patient education, and clinical documentation.
Why Nomenclature Matters
In clinical and research conversations about Alzheimer’s disease risk, the terms APOE ε4, ApoE4, and APOE4 appear interchangeably — yet they are not the same thing. Each term belongs to a distinct level of biological organization: the gene, the allele, and the protein. Conflating them introduces ambiguity into scientific communication and, more practically, into the conversations clinicians have with patients about genetic testing results.
The Advisory Group on Risk Evidence Education for Dementia (AGREE Dementia), whose nomenclature guidance was authored by Washington University neurologist Suzanne Schindler, MD, PhD, provides the clearest published framework for correct usage. The conventions below are consistent with that guidance and with standard practice across Nature Neuroscience, JAMA Neurology, Lancet Neurology, and Alzheimer’s & Dementia.
Three Terms. Three Distinct Meanings.
| Term | What It Refers To | Correct Usage Example |
|---|---|---|
| APOE Capitalized, italicized | The gene locus on chromosome 19 (19q13.32) encoding apolipoprotein E. The human gene symbol, by HGNC convention, is always italicized. | “The APOE gene has three common alleles: ε2, ε3, and ε4.” |
| APOE ε4 Gene + allele designation | The ε4 allele of the APOE gene — a specific variant defined by two SNPs (rs429358 C; rs7412 C) that result in arginine at positions 112 and 158 of the mature protein. Alleles are designated with the Greek letter epsilon (ε), not the Roman letter E. | “APOE ε4 carriers face a 3–4× elevated lifetime risk for late-onset Alzheimer’s disease.” |
| ApoE4 Protein isoform | The apolipoprotein E4 protein isoform — the 299-amino-acid glycoprotein (34 kDa) encoded when an individual carries the ε4 allele. By convention, the protein abbreviation is not italicized and begins with a capital A followed by lowercase letters. | “ApoE4 impairs amyloid-β clearance through glymphatic and perivascular pathways more than ApoE3 does.” |
Genotype Notation
A patient’s full genotype is expressed as the two alleles they carry, separated by a slash: ε3/ε4 (one copy) or ε4/ε4 (two copies, homozygous). The gene symbol is typically written once before the slash notation: APOE ε3/ε4. The pairing always uses the Greek epsilon symbol, never Roman E — writing “E3/E4” is a common error in non-specialist publications.
The Molecular Basis: One Gene, Two SNPs, Three Isoforms
The nomenclature difference is not arbitrary. It reflects a real distinction in molecular biology. The three common APOE alleles — ε2, ε3, and ε4 — arise from two single nucleotide polymorphisms (SNPs) on chromosome 19: rs429358 and rs7412. These two variants determine the amino acid at positions 112 and 158 of the mature protein:
| Allele | Position 112 | Position 158 | Protein Isoform |
|---|---|---|---|
| ε2 | Cys | Cys | ApoE2 |
| ε3 | Cys | Arg | ApoE3 (ancestral/reference isoform) |
| ε4 | Arg | Arg | ApoE4 — highest AD risk isoform |
The arginine-at-112 substitution in ApoE4 causes domain interaction between the N-terminal receptor-binding domain and the C-terminal lipid-binding domain — a structural change absent in ApoE3 — that alters lipoprotein binding preferences and is thought to underlie much of its differential effect on amyloid-β metabolism and neuroinflammation.
Weisgraber et al., J Biol Chem (1981); Mahley & Huang, Neuron (2012)
Clinical Relevance: Why the ε4 Allele Is the Focus
The APOE ε4 allele is the strongest known common genetic risk factor for late-onset Alzheimer’s disease, a relationship first established by Strittmatter and colleagues in 1993 and confirmed across hundreds of subsequent genome-wide association studies. Carriers of one ε4 allele (ε3/ε4) face approximately 3–4 times the population baseline risk; homozygous carriers (ε4/ε4) face an 8–12-fold elevation — with cumulative risk to age 85 estimated at approximately 30% and 50%, respectively.
In this context, the terms are used as follows in the peer-reviewed literature:
- APOE ε4 carrier — a person who carries one or two copies of the ε4 allele (genetic designation)
- APOE ε4/ε4 homozygote — a person carrying two copies (genotype designation)
- ApoE4 protein — the functional isoform and its downstream biological effects (molecular/mechanistic designation)
- APOE4 (no space, no epsilon) — an informal shorthand seen in lay communication and some research abbreviations; acceptable but less precise
Clinical Note — ARIA Risk & Anti-Amyloid Therapies
In contemporary trials of anti-amyloid immunotherapy — including lecanemab (CLARITY AD) and donanemab (TRAILBLAZER-ALZ 2) — APOE ε4 genotype stratification is a primary safety and efficacy variable. The APOE ε4/ε4 homozygote subgroup carries substantially elevated ARIA-E and ARIA-H risk compared with non-carriers, a distinction that directly informs candidacy determinations. Precise genetic terminology in documentation is therefore not merely academic.
van Dyck et al., NEJM (2023); Sims et al., JAMA (2023)
Quick Reference: Which Term to Use When
| Context | Preferred Term | Example |
|---|---|---|
| Genetic testing result or carrier status | APOE ε4 carrier | “The patient is an APOE ε3/ε4 carrier.” |
| Molecular or mechanistic discussion | ApoE4 (protein) | “ApoE4 preferentially binds VLDL over HDL.” |
| Epidemiology or risk stratification | APOE ε4 | “APOE ε4 prevalence is ~14% globally.” |
| Gene symbol (formal scientific writing) | APOE (italicized) | “The APOE gene is located on chromosome 19q13.” |
| Lay communication / patient materials | APOE4 (acceptable shorthand) | “About 1 in 4 people carry the APOE4 gene variant.” |
The Bottom Line
The correct terminology follows this hierarchy:
- APOE — the gene (italicized, all caps)
- APOE ε4 — the allele conferring risk (gene + Greek epsilon designation)
- ApoE4 — the protein isoform and its biological effects (mixed case, not italicized)
In everyday clinical usage, APOE ε4 carrier is the standard for describing patient genotype. ApoE4 is the appropriate term when discussing mechanistic pathways — amyloid clearance, lipid transport, neuroinflammation, or synaptic function. When writing for patients, the shorthand APOE4 is widely understood and acceptable, provided the context makes clear that you are referring to a gene variant and the elevated risk it confers.
Selected References
- Strittmatter WJ et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90(5):1977–1981.
- Weisgraber KH et al. Human E apoprotein heterogeneity: cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981;256(17):9077–9083.
- Mahley RW & Huang Y. Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron. 2012;76(5):871–885.
- Liu CC et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–118.
- Raulin AC et al. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Mol Neurodegeneration. 2022;17(1):72.
- van Dyck CH et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21.
- Sims JR et al. Donanemab in early symptomatic Alzheimer’s disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512–527.
- Genin E et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011;16(9):903–907.
- Schindler SE (AGREE Dementia). Apolipoprotein E Nomenclature. Advisory Group on Risk Evidence Education for Dementia. 2020. Available at: agreedementia.org/apoeterms.
- HGNC. Gene symbol report: APOE. HUGO Gene Nomenclature Committee. genenames.org.
APOE4 Insights Premium
Go deeper on the science that matters for APOE ε4 carriers.
Members receive full-text clinical reviews, graded evidence tables, and weekly peer-reviewed content — written by a neurologist and pain medicine specialist who carries the gene himself.
Become a Member →
